GSK 4382276A
Alternative Names: Avian influenza vaccine; Flu-mRNA; FLU-SV-mRNA; GSK-4382276; GSK-4382276ALatest Information Update: 28 May 2025
At a glance
- Originator CureVac
- Developer CureVac; GSK
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Influenza-virus-infections(In the elderly, Prevention, In adults) in United Kingdom (IM)
- 12 Sep 2024 Adverse events and immunogenicity data from a phase II trial in Influenza virus infections (Prevention) released by GlaxoSmithKline
- 12 Sep 2024 GSK plans a phase III trial in Influenza virus infections (Prevention) (IM, Injection)